U.S. Drug Prices Remain Steep Despite New Medicare Negotiations

The U.S. government's new Medicare-negotiated drug prices are still significantly higher than those in several other high-income countries. Despite the Biden Administration's Inflation Reduction Act aiming to reduce costs, an analysis reveals U.S. prices remain more than double and sometimes five times as high as prices in Australia, Japan, Canada, and Sweden.

The U.S. government's recent Medicare-negotiated drug prices remain significantly higher than those in other high-income countries, a Reuters review reveals.

Despite the Biden Administration's Inflation Reduction Act aiming to lower costs, these U.S. prices average more than double and occasionally five times those in Australia, Japan, Canada, and Sweden.

This first-ever disclosure of actual drug prices by Medicare highlights the financial burden on the over 67 million people covered, with potential savings of $6 billion expected in 2026.